📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Oncoinvent

1.1 - Company Overview

Oncoinvent Logo

Oncoinvent

Headquarter: Norway
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of radiopharmaceutical cancer treatments, including Radspherin for metastatic cancers in body cavities using alpha-emitting microparticles. Operates a GMP-standard facility for radiopharmaceutical production supporting large multi-center clinical studies. Develops a pipeline of radiotherapeutic, radioimmunotherapeutic and immunotherapeutic products, with proprietary antibodies as targeting modules.

Products and services

  • GMP standard production facility: A GMP-standard radiopharmaceutical manufacturing facility producing Radspherin and other radiopharmaceuticals, with capabilities for large multi-center clinical studies
  • Pipeline: Multi-program development of radiotherapeutic, radioimmunotherapeutic, and immunotherapeutic products for various solid cancers, using novel-materials-based approaches derived from known physical and chemical principles
  • Radspherin: A radiopharmaceutical product engineered for metastatic cancers in body cavities, utilizing alpha-emitting radioactive microparticles to deliver localized therapeutic radiation

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Oncoinvent

CiMaas Logo

CiMaas

HQ: The Netherlands Website
  • Description: Provider of immunotherapies engaging the immune system to treat cancers not cured by current standard of care, including CIM201 adoptive NK cell therapy using proprietary NK expansion for high cytotoxicity; CIM101 F012 feeder cells to rapidly expand NK cells under licensing; and CIM401 adoptive CAR-NK therapy targeting solid tumors, initially breast cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CiMaas company profile →
Tobira Therapeutics Logo

Tobira Therapeutics

HQ: United States Website
  • Description: Provider of research, discovery, acquisition, development, and commercialization of antiviral compounds for treating life-threatening and life-altering infectious diseases, including HIV/AIDS and hepatitis; develops TBR-652 and TBR-220 antagonists.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Tobira Therapeutics company profile →
Flexus BioSciences Logo

Flexus BioSciences

HQ: United States Website
  • Description: Provider of novel anti-cancer therapeutics created, developed, and commercialized through an innovative application of unexploited insights in immunology; privately-held biopharmaceutical company founded in 2013 and headquartered in San Carlos, California.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Flexus BioSciences company profile →
Trubion Logo

Trubion

HQ: United States Website
  • Description: Provider of biopharmaceutical product candidates for autoimmune diseases and cancer, developing novel single-chain polypeptide proteins built with its SMIP custom drug assembly technology.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Trubion company profile →
Immunservice Logo

Immunservice

HQ: Germany Website
  • Description: Provider of interleukin-2-based immunotherapy solutions, developing biomimetic medicines, vaccines, and growth factors, and offering IL-2 bioactivity measurements and resources for diagnostic and pharmaceutical development. Focuses on human and animal immunotherapy and human cell therapy, enhancing immune cell proliferation and targeting cancer and virus cells.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Immunservice company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Oncoinvent

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Oncoinvent

2.2 - Growth funds investing in similar companies to Oncoinvent

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Oncoinvent

4.2 - Public trading comparable groups for Oncoinvent

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Oncoinvent

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Oncoinvent

What does Oncoinvent do?

Oncoinvent is a provider of radiopharmaceutical cancer treatments, including Radspherin for metastatic cancers in body cavities using alpha-emitting microparticles. Operates a GMP-standard facility for radiopharmaceutical production supporting large multi-center clinical studies. Develops a pipeline of radiotherapeutic, radioimmunotherapeutic and immunotherapeutic products, with proprietary antibodies as targeting modules.

Who are Oncoinvent's competitors?

Oncoinvent's competitors and similar companies include CiMaas, Tobira Therapeutics, Flexus BioSciences, Trubion, and Immunservice.

Where is Oncoinvent headquartered?

Oncoinvent is headquartered in Norway.

How many employees does Oncoinvent have?

Oncoinvent has 1,000 employees 🔒.

When was Oncoinvent founded?

Oncoinvent was founded in 2010 🔒.

What sector and industry vertical is Oncoinvent in?

Oncoinvent is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Oncoinvent

Who are the top strategic acquirers in Oncoinvent's sector and industry

Top strategic M&A buyers and acquirers in Oncoinvent's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Oncoinvent?

Top strategic M&A buyers groups and sectors for Oncoinvent include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Oncoinvent's sector and industry vertical

Which are the top PE firms investing in Oncoinvent's sector and industry vertical?

Top PE firms investing in Oncoinvent's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Oncoinvent's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Oncoinvent's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Oncoinvent's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Oncoinvent include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Oncoinvent's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Oncoinvent?

The key public trading comparables and valuation benchmarks for Oncoinvent include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Oncoinvent for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Oncoinvent with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Oncoinvent's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Oncoinvent with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Oncoinvent's' sector and industry vertical?

Access recent funding rounds and capital raises in Oncoinvent's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Oncoinvent